These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 3103382)

  • 21. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

  • 23. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 24. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.
    Binde CD; Tvete IF; Gåsemyr J; Natvig B; Klemp M
    Br J Clin Pharmacol; 2018 Sep; 84(9):1917-1927. PubMed ID: 29847694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selegiline, pregnancy, and Parkinson's disease.
    Kupsch A; Oertel WH
    Mov Disord; 1998 Jan; 13(1):175-6. PubMed ID: 9452347
    [No Abstract]   [Full Text] [Related]  

  • 27. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are there MAO inhibitors specific for dopamine metabolism?
    Youdim MB; Holzbauer M
    Adv Biochem Psychopharmacol; 1977; 16():349-58. PubMed ID: 329649
    [No Abstract]   [Full Text] [Related]  

  • 30. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.
    Lew MF
    Expert Rev Neurother; 2005 Nov; 5(6):705-12. PubMed ID: 16274328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
    Riederer P; Müller T
    J Neural Transm (Vienna); 2018 Nov; 125(11):1751-1757. PubMed ID: 29569037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selegiline HC1: Selective MAO-type B inhibitor.
    Koller WC; Giron LT
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
    [No Abstract]   [Full Text] [Related]  

  • 36. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 37. Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease.
    Park HR; Kim J; Kim T; Jo S; Yeom M; Moon B; Choo IH; Lee J; Lim EJ; Park KD; Min SJ; Nam G; Keum G; Lee CJ; Choo H
    Bioorg Med Chem; 2013 Sep; 21(17):5480-7. PubMed ID: 23810676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Parkinson's disease].
    Mizuno Y
    No To Shinkei; 1994 Mar; 46(3):217-27. PubMed ID: 7910751
    [No Abstract]   [Full Text] [Related]  

  • 39. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 40. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.